The anti-apoptotic protein B-cell lymphoma 2 (BCL2) is a key regulator of the intrinsic apoptotic pathway and is often overexpressed in chronic lymphocytic leukemia (CLL) cells. That’s why BCL2 represents an important therapeutic target for CLL, and joining Dr. Charles Turck to look at Venetoclax, a treatment option that targets this protein is Dr. Nicole Lamanna, an Associate Clinical Professor of Medicine at Columbia University Medical Center in New York.

Neurogenic orthostatic hypotension (nOH) is a subset of orthostatic hypotension and is prevalent in patients with autonomic dysfunction.1,2 In these patients, there is insufficient compensatory peripheral release of norepinephrine, the major neurotransmitter responsible for blood pressure maintenance, upon standing or following postural change.2-4 Due to this norepinephrine deficiency, there is inadequate vasoconstriction to maintain blood pressure or cerebral blood flow.1,5 This may lead to symptoms of nOH which may increase the risk of falls and lead to serious consequences.2,3,6

Here. Dr. Satish Raj, Professor of Cardiac Sciences at the Libin Cardiovascular Institute at the University of Calgary's Cumming School of Medicine and Medical Director of Calgary Autonomic Clinic, discusses the pathogenesis of nOH, as well as the mechanisms behind therapeutic approaches to controlling its effects.

References:

1. Palma JA, Kaufmann H. Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension. Mov Disord Clin Pract. 2017;4(3):298-308.
2. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011:21(2) 69-72.
3. Low PA. Neurogenic orthostatic hypotension: pathophysiology and diagnosis. Am J Manag Care. 2015;21(suppl 13):s248-s257.
4. Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation. 2009:119(1):139-146.
5. Freeman …

Several questions are often brought to light when it comes to detecting and diagnosing Gaucher disease, such as how does it present, what genetic factors to consider, and how to go about making an accurate diagnosis. Here to answer those and other questions are practicing hematologist oncologist Dr. Coy Heldermon and neurogeneticist Dr. Heather Lau.

For more information on the diagnostic and therapeutic landscape for Gaucher disease, including access to Sanofi Genzyme Rare Disease Registries, visit Gauchercare.com/hcp, a Sanofi Genzyme website.

MAT-US-2024074 2/2021

With the ongoing COVID-19 pandemic threatening our health and adding burden to our healthcare system, it’s more important than ever to educate patients on the flu and its symptoms. Here to share tips on how we can help prepare for, diagnose and treat flu this season are Dr. Casey Lafferty and Physician Assistant Doctorate Dr. Eder Hernández.

This information is intended for US audiences only.

With the development of technologies paired with an enhanced understandings of the AML genomic landscape, it’s become possible to develop targeted AML therapies. Joining Dr. Charles Turck to explore Venetoclax and its role in current AML treatment paradigms are Drs. Uma Borate and Harry Erba.

Patients with type 2 diabetes face a higher risk of cardiovascular morbidity and mortality than adults without diabetes. How does this understanding specifically affect the way cardiologists manage their patients with type 2 diabetes? Joining Dr. Charles Turck to explore recently updated recommendations and their impacts on cardiology practice is interventional cardiologist Dr. Joshua Stolker.

To view the 2020 American College of Cardiology Expert Consensus Decision Pathway click here.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

© 2021 Novo Nordisk All rights reserved. US20DI00435 February 2021

TAVR-related stroke is a real risk that can seriously impact your patients' quality of life. In this video, Drs. Hemal Gada and Vijay Iyer sit down to discuss the effects of stroke, the role of cerebral embolic protection, and the importance of protecting patients' brains.

Physicians in this episode were compensated for their participation.

Media provided courtesy of Boston Scientific or its affiliates.

Dr Dustin Deming presents an overview of BRAF-mutant metastatic colorectal cancer (CRC). He reviews the incidence of and prognosis for BRAF-mutant metastatic CRC. Phenotypic characteristics and the molecular pathway associated with BRAF-mutant metastatic CRC are also discussed.

© 2021 Pfizer Inc. All rights reserved. PP-BCE-USA-0284 January 2021

Infertility is defined as being unsuccessful in achieving pregnancy with unprotected intercourse for 12 months or for 6 months in women over 35. And since evaluation should be offered to any patient who meets this definition, reproductive endocrinologist Dr. Priya Maseelall is here to review some key evaluation strategies for infertility.

Quest Diagnostics Center of Excellence for fertility testing, ReproSource, is a national leader in specialty fertility diagnostic services. While ReproSource is a Quest Diagnostics affiliate, ReproSource and Quest are separate companies. As such, health plan access, test ordering, and billing processes may differ from those of Quest Diagnostics. Please note that ReproSource is not a Medicare/Medicaid provider. For more information, please contact ReproSource at 1.800.667.8893 or visit ReproSource.com/Contact

Reference:

1. Agarwal A, Mulgund A, Hamada A, Chyatte MR. A unique view on male infertility around the globe. Reprod Biol Endocrinol. 2015;13:37. Published 2015 Apr 26. doi:10.1186/s12958-015-0032-1

As sexually transmitted infections (STIs) are on the rise, it’s more important than ever to test our patients in addition to treating them so that we can help put a stop to the spread. But what clinical symptoms are linked to STIs and STI-related conditions? Which diagnostic tests should be done? And can untreated STIs have lasting impacts? Those are the exact questions Dr. Maria Trent explores in this program.